put some bullet here. eventhough is high risk

Still ok la… easy u can buy above RM50 then discount RM15, still worth it. Indirectly can push up the sales for Q2.. hihi

Xiao xiami.. U mean?

Don't worry I will hold it for long term

Mostly q1 result. From Q to Q maybe not good. This only my estimation, but operator look like going to press down the price. But anyhow hope before AGM have some movement. Now buying power very weak.

Hey guys price foreseen will b further press down. For those who can't stay can sell it now. Probably Q1 result may not good, as per pass history. For long term no impact, may collect some when price down

就是啊。大家只想赚快钱。而忘记了风险。放弃这里蛮不值得。

Guys, please be patient. If you bought at previous low price and sell now then is ok. If you go in at high price like 0.285 please hold it. This company will reward u. don’t sell it at loss.

Sorry to correct my statement, free shipping for every purchase more than RM350 within peninsular Malaysia.

I believed Bioalpha going to have announcement soon with the e-constant launch. Temporary what I saw is free shipping, and for those who get the free voucher come together with the annual report also can use at this online shopping. Just key in your voucher code before make a payment. Point is rewarded for every transaction.
Good move for Bioalpha…

still got countdown... hahahaha...

From Bioalpha FB can see they keep on push on the constant franchise, this is the easy to increase their company revenue, to inline something like caring pharmacy. Beside, e-constant is start to take place with the launching of merit system.

Confidence that this year bioalpha will bring some different to investor.

https://m.facebook.com/profile.php?id=100009656081277&tsid=0.1626629886132207&source=result

we are playing for long term. not need to care so much.

Based on history, Q1 result won't be good. Hope this year is different

before AGM sure got some show....

Maybe. Since they collect quite some time at 0.265

look at trend price will drop to 260

Above info is from one of the article.

Q117 would have 133.333m more shares from right issue, 29m share issuance scheme option(more to come as they are allow to issue up to 279.999m) and 133.333m warrant.

What I know is total ESOS will be around 29m share. So, for those cannot tahan can sell it tml. Don't say I not tell u all.

yeah... all sell in Thursday... good bye to u all.... hope u all not come back to this forum anymore..

You can see how frequent of VS to issue ESOS. But the stock price is at 2.01 as at today.
So, whether this impact to company share price?? my answer is NO..........
In fact, VS is growing from time to time. and company reward to employee.
I can say is only company who care of employee will only do this, how many public listed can do this. You can see Bioalpha is just rewarding to their by contributing for last few year. They are geting significant growth. So what, such a good company sharing their profit, somemore the ESOS not impact so much to EPS. Anything to complaint about this company.

History of ESOS for company VS.
21-Apr-2017 25-Apr-2017 ESOS 200,000 0.700 Additional Listing Detail
18-Apr-2017 19-Apr-2017 ESOS 145,000 0.700 Additional Listing Detail
06-Apr-2017 07-Apr-2017 ESOS 50,000 0.700 Additional Listing Detail
30-Mar-2017 31-Mar-2017 ESOS 40,000 0.700 Additional Listing Detail
22-Mar-2017 23-Mar-2017 ESOS 23,000 0.700 Additional Listing Detail
21-Mar-2017 22-Mar-2017 ESOS 5,000,000 0.700 Additional Listing Detail
02-Mar-2017 03-Mar-2017 ESOS 40,000 0.700 Additional Listing Detail
21-Feb-2017 22-Feb-2017 ESOS 310,000 0.700 Additional Listing Detail
15-Feb-2017 16-Feb-2017 ESOS 345,000 0.700 Additional Listing Detail
02-Feb-2017 03-Feb-2017 ESOS 5,000 0.700 Additional Listing Detail
13-Jan-2017 16-Jan-2017 ESOS 5,000,000 0.700 Additional Listing Detail
09-Jan-2017 10-Jan-2017 ESOS 4,000,000 0.700 Additional Listing Detail
30-Dec-2016 03-Jan-2017 ESOS 90,000 0.700 Additional Listing Detail
20-Dec-2016 21-Dec-2016 ESOS 64,000 0.700 Additional Listing Detail
14-Dec-2016 15-Dec-2016 ESOS 110,000 0.700 Additional Listing Detail
07-Dec-2016 08-Dec-2016 ESOS 5,000 0.700 Additional Listing Detail
01-Dec-2016 02-Dec-2016 ESOS 300,000 0.700 Additional Listing Detail
28-Nov-2016 29-Nov-2016 ESOS 100,000 0.700 Additional Listing Detail
19-Oct-2016 20-Oct-2016 ESOS 125,000 0.700 Additional Listing Detail
12-Oct-2016 13-Oct-2016 ESOS 510,000 0.700 Additional Listing Detail
07-Oct-2016 10-Oct-2016 ESOS 90,000 0.700 Additional Listing Detail
23-Sep-2016 26-Sep-2016 ESOS 25,000 0.700 Additional Listing Detail
19-Sep-2016 20-Sep-2016 ESOS 20,000 0.700 Additional Listing Detail
08-Sep-2016 09-Sep-2016 ESOS 45,000 0.700 Additional Listing Detail
02-Sep-2016 05-Sep-2016 ESOS 30,000 0.700

Some Situation in Malaysia:

Real situation here is whereby rather than concern about the benefits of shareholders (who is also owner of the company), the directors in the some companies care about themself more. One of the infamous thing that board of directors like to do is issue a large amount of ESOS and when they reach the limit of ESOS, they enlarge the limit. (No limit on irrationality either)

(A recent example would be VS, increasing its ESOS from 10% to 15% of total shares issued; I don't own shares of VS, i don't know what is its business, just giving an example)

The board of directors will eloquentlly argued that the issuing ESOS is to make sure all its outstanding employees contribute more to the company by increasing it ownership feeling and increase the willingness to retent in the company.

HOWEVER, THINK TWICE. Look into the ESOS scheme (another company that voraciously issue ESOS is Favelle Favco, IOI corp and IOI property). WHO GET MOST OF THE ESOS? The CEO/ directors of the board who are ALSO ALREADY THE LARGEST SHAREHOLDER. Meanwhile, the employees will get the smallest slices of the cake (ESOS subscription right). Directors who use the fund of the shareholders to fatten their own wallet is not a honest-to-god act.

ESOS will dilute the EPS, ROE and DY (anything else good missed?). Using the money and trust from the shareholders to voraciously enlarge their already biggest shareholding via ESOS, well can be viewed as a warning sign of no integrity in the management board. Furthermore, you will notice that the one who will rubberstamps the ESOS will be the largest shareholders as well. More viciously, they enlarge it when it limit of ESOS is reached. If such a company also "coincidentally" pays a lot of salary to its CEO, these combinations mean no good to your own wallet. ESOS is not all bad, it is a good strategy, if used prudently.

Look back for Bioalpha, as at today around 0.4% ESOS of total share issue. This is only the small amount to reward to employee. But anyhow, this type of scheme need to monitor, don't miss use. Anything also have pros and cons. but what I can see is this really is to reward to his staff like recently just get promote to CFO, Goh Siow Ching.

If another case is issue the of ESOS, but then exercise by William main shareholder then this consider of misuse like mention in statement above.

http://klse.i3investor.com/additionalListing/0179/09-May-2017/16876_1720062996.jsp

Additional

This is not because of why the CFO sold it. Is ESOS system that company gives the reward to specific employee for exercise it.

how ESOS work.

Employee stock options (ESOs) are call options on a company's common stock granted to a select group of its employees. Certain restrictions on the option provide a financial incentive for employees to align their goals with those of the company's shareholders.

If an employee working for company XYZ gets an option on 100 XYZ shares at $10 and XYZ's stock price goes up to $20, the employee can exercise the option and buy the 100 XYZ shares at the $10 strike price, sell them on the market for $20 each, and pocket the $1,000 difference ($2,000 - $1,000 = $1,000). If XYZ's stock never goes above the $10 strike price, the employee lets the option expire at no real cost to themselves.

Jika u simpan dari 2 tahun lalu, sikarang u sudah untung lo.

So, use mouth talk is easy, are u able to hold for 2 years? Do u have such patient.

Investment is talking about future, how is the direction of the company. Bioalpha, from previous only run production, now almost 1 stop services, raw material, production, distribution, marketing, pharmacy, online shopping. You can see, no much risk to impact Bioalpha to grow. Not need to worry about raw material price increase, have own pharmacy to distribute the product, so there only need to focus on R&D, and improve production efficiency.
So what, investment must look at this point.

paulcheong, simple moving average period 1 and period 2 how to determine

PAULCHEONG, thank a lot..

technical close higher at 0.27 for today. Another 2 weeks going to have AGM. Is time to move, I believe management sure have some good news to announce. Move to main board????

PAULCHEONG, how to see death cross ya..

If u thinks this counter is waste ur time then pls move out from here. Go invest for such so call high return. We are looking for future of this company, not mean today invest tml immediate get profit. Then better go gambling more faster.

I'm just a potato

2017 activities plan to do. (Source Annual Report)

a)Herbal Farming
What we plan to do – Our Group aims to be fully self-sufficient for herbal-based raw materials as it allows us to have better quality control and enjoy higher profit margins. During the year under review, we have started land clearing activities under Phase 2 expansion at the Pasir Raja herbal park, which involves an area of 879.7 acres. We aim to complete land clearing and planting of herbs under Phase 2 of Pasir Raja herbal park over the next 36 months. We will be able to harvest these plantations in a few years when the plants mature. We estimate that by 2020, the plants would reach maturity, potentially yielding a harvest of some 450 metric tonnes of herbs per annum – 100 metric tonnes from Phase 1 and 350 metric tonnes from Phase 2 of Pasir Raja herbal park. The output shall fully satisfy our in-house requirement for herbal-based raw materials, and the excess shall be sold to external parties to create additional revenue flow.

b)Research and Development (“R&D”)
Our R&D team will continue to develop new formulations, especially for the planned roll-out of new products across our key markets in Malaysia, Indonesia, and China over next two years. Meanwhile, for the pre-clinical research studies on the “high-value herbal” products, the results have been very encouraging and we plan to move forward to commence clinical research studies in 2017.

c)Processing and Manufacturing
The Indonesian plant will commence manufacturing products for sale in the local Indonesian market. Meanwhile, back home in Malaysia, we will also be upgrading some machinery and equipment at our plants to further improve our capability and production efficiency.

d)Retail
On the pharmacy expansion, our strategy is to increase our outlets via franchise model and we target to double the number of existing outlets by end of 2017. We have identified Kelantan, Johor, Kedah and selected places in Klang Valley as the potential locations for these new outlets. We will also continue to leverage on our strategic partnership with ANGKASA to promote the franchise opportunity to their 8 million members from some 12,000 cooperatives.
We are also embarking on another exciting project this year – the e-Constant online shop with referral programme. The e-Constant programme shall be made available exclusively for ANGKASA members where they could register as referral agents, and subsequently set up their personal e-Constant virtual shop to sell the products through the referral mechanism. In the process, the ANGKASA members will be able to earn some income. Bioalpha, through Constant Pharmacy, will manage the product fulfilment and delivery process. The e-Constant programme is part of our push to further promote our e-commerce initiatives

You can see Caring pharmacy how success is it. I believed Constant also will be one the market player in near future. With target double up the outlet in 2017, this probably with push up the share price.

De zhi, I agreed with you. this type of counter wont fluctuate so much based on market news. although Bioalpha also wont move fast compared to other counters. But slowly growth is good. So, this play a significant role in our stock portfolio.

N225. How this process?

aiyo... go in so high price morning... now go down..

From here you can see how operator to flush out all impatient player.

Just put aside first, will reward soon. This counter is low risk. It plays a significant role in your portfolio.

Still hold it la... join other area... enjoy the party ma

I go in 0.68 will it be too late

Look no hope. Remained to press down.

IncredibleThings , see today blog. Similar thing mention as what u share with us.

Spike, Sleep, Spike Up Again with Volume - BIOHLDG, IWCITY, MMSV, SYSTECH, OCNCASH

http://klse.i3investor.com/blogs/gainvestor10sai.blogspot.com/121965.jsp

haha... busy whole day.. last minute push back to 265

climb up slowly..

today will close at 0.27....

So what I want to mention here is, MD William mention Bioalpha will make announcement after few months to transfer to main board. I believed this is possible; they are just waiting the audited report. Right now has been issued, or possibility with make announcement to public during AGM. So, how the share price going to be…….?????? Sure will rocket up… pls collect ticket right now.